Indivior Pharmaceuticals, Inc. 8-K

What Happened

• On February 26, 2026, Indivior Pharmaceuticals, Inc. announced and furnished a press release reporting its financial results for the period ended December 31, 2025 (Item 2.02). The press release is filed as Exhibit 99.1 to the Form 8-K.
• The company also disclosed Regulation FD materials on February 26, 2026, posting presentation materials and an updated corporate presentation on its website (furnished as Exhibits 99.2 and 99.3 to the Form 8-K).

Key Details

• Date of disclosure: February 26, 2026.
• Financial results reported for the period ended December 31, 2025 (details in Exhibit 99.1 press release).
• Presentation materials dated February 26, 2026 (Exhibit 99.2) and an updated corporate presentation (Exhibit 99.3) were posted under Regulation FD.

Why It Matters

• The press release contains the company’s most recent earnings and financial condition information for the period ended Dec 31, 2025 — essential data for assessing revenue, profitability, and near-term performance.
• The posted presentations provide investor-facing slides and updates that may include management commentary, business trends, or strategic highlights. Investors should review the exhibited press release and presentations for the specific figures and narrative behind the results.